ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ACHV vs NNNN // 10Y YIELD & FRED MACRO BETA

Achieve Life Sciences Inc. (NASDAQ) VS. Anbio Biotechnology (Class A) (NASDAQ) • 15-METRIC TALLY: ACHV 2 — NNNN 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ACHV VS. NNNN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ACHV NNNN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 87.20% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 17.00% -52.00 NNNN /roic <GO>
EV/EBITDA & P/E Valuation — 91.5x — TIE /valuation <GO>
Free Cash Flow Yield -6.69% -1.26% -5.43 NNNN /fcf-yield <GO>
Operating Margin — 66.70% — TIE /operating-margins <GO>
Net Profit Margin — 68.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — 5.60% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 5/9 -3.00 NNNN /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 46.4 29.4 +16.98 ACHV /rsi-technicals <GO>
10Y Yield & FRED Macro Beta ACTIVE — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 77.7x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $739.9M $535.3M $204.6M ACHV /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ACHV REV NNNN REV ACHV GROSS % NNNN GROSS % ACHV FCF NNNN FCF
FY 2025 $0 $8.6M — 87.2% -$49.5M -$6.7M
FY 2024 $0 $8.2M — 71.9% -$29.8M $2.1M
FY 2023 $0 $6.7M — — -$24.5M $898.4K
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ACHV // BETA —
NNNN // BETA —